Canada markets closed
  • S&P/TSX

    21,216.15
    +3.76 (+0.02%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.94 (+0.21%)
     
  • CAD/USD

    0.8091
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    83.98
    +1.48 (+1.79%)
     
  • BTC-CAD

    74,810.27
    -1,640.76 (-2.15%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • GOLD FUTURES

    1,793.10
    +11.20 (+0.63%)
     
  • RUSSELL 2000

    2,291.27
    -4.92 (-0.21%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • NASDAQ

    15,090.20
    -125.50 (-0.82%)
     
  • VOLATILITY

    15.43
    +0.42 (+2.80%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • CAD/EUR

    0.6942
    -0.0010 (-0.14%)
     

ITRM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Iterum Therapeutics Plc Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Iterum Therapeutics Plc (NASDAQ: ITRM) alleging that the Company violated federal securities laws.

Class Period: November 30, 2020 and July 23, 2021
Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ITRM:
https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19830&from=5

Iterum Therapeutics Plc NEWS - ITRM NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Iterum you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Iterum securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ITRM lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97513

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting